Back to library
Loading…
inflammation · The New England Journal of Medicine · 2017
This trial found that anti-inflammatory therapy with canakinumab significantly lowered the risk of recurrent cardiovascular events in patients with prior myocardial infarction and elevated C-reactive protein.
Ridker PM, Everett BM, Thuren T, et al.
This trial found that anti-inflammatory therapy with canakinumab significantly lowered the risk of recurrent cardiovascular events in patients with prior myocardial infarction and elevated C-reactive protein.